Our Platform
Our Respiro
Platform
Where connected inhalers meet intelligent insights.
Our clinically proven platform combines CE‑marked inhaler sensors, digital experiences for patients and providers, and a secure, scalable cloud — delivering actionable insights that improve adherence and outcomes.
adherence 1
inhaler usage 2
hospitalizations 3
healcare cost 4
Respiro unites four integrated components that work together to support patients, providers, and partners.
Sensors
Our connected sensors capture key medication usage and inhalation metrics, delivering real-time insights via Bluetooth.
- Tracking adherence and inhalation quality
- Add-on modules for existing inhalers
- Direct integration into devices like Plastiape’s RS01X
- Automatic data sync with extended battery life
Patient Experience
Respiro empowers patients with personalized insights and timely support, making treatment easier to follow and progress simple to share.
- Personalized insights for habit-building
- Timely reminders and inhalation feedback
- Trigger detection and symptom forecasting
- Easy sharing with care teams for personalized treatment
Remote Patient Monitoring
Respiro gives healthcare professionals continuous, objective data on inhaler use and technique, supporting timely, personalized interventions.
- Real-time monitoring of patient medication use
- Objective inhaler data and inhalation analytics
- Actionable insights to optimize care
- Alerts for high-risk patients to guide intervention
Cloud Platform
Respiro’s secure cloud delivers inhalation data analytics and integration tools, enabling seamless collaboration with third-party systems.
- Real-world data engine synthesizing inhaler insights
- Integrations via Webhooks, APIs, and SDKs
- Scalable microservices architecture
- Built under ISO 13485:2016 QMS for global compliance
How can Amiko work with you?
Pharma Company
Leverage Respiro to improve patient outcomes, strengthen treatment adherence, and unlock actionable, real-world data.
Health provider
Partner
Integrate Respiro into your portfolio to accelerate innovation, expand your healthtech offering, and create new value for your customers.
Researcher
Harness Respiro’s connected inhalers and analytics to generate high-quality evidence, accelerate studies, and advance inhaled medicine.
Footnotes
Study Results on Medical Cost Savings Conducted by Risk Strategies Consulting, June 2024.
ROI Explanation: The return on investment (ROI) is calculated as the untruncated gross medical savings ($3,012) divided by program fees ($989) as reported in the study. This calculation is based on the study’s specific data.
Surgery Reduction: These figures are based on comparative studies between Sword participants and a control group receiving traditional care.
Sword BoB 2023, of members who enroll in our programs with moderate to severe pain and by the end of the program have only mild or no pain.